Core Insights - IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately, to enhance leadership during a critical growth phase [1][2] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases [1][6] - The company's lead program, INB-100, targets acute myeloid leukemia, while other programs include INB-200 and INB-400 for glioblastoma, and INB-600 for oncology and autoimmune indications [6] Leadership and Experience - Dr. Rochlin has over 17 years of experience in biotechnology, including roles in scientific research, intellectual property, business development, and clinical manufacturing [3] - Prior to her role at IN8bio, she served as Chief Business Officer at Curadigm, contributing to the company's spin-out from Nanobiotix [3] Clinical Advancements - Under Dr. Rochlin's leadership, IN8bio has advanced its clinical programs, including the development of INB-619, which has shown promising preclinical results in achieving complete B cell depletion with minimal adverse effects [4] - The company has made significant progress in its clinical manufacturing program, supporting multiple Phase 1 and 2 clinical trials in glioblastoma and hematological cancers [4] Future Outlook - Dr. Rochlin expressed confidence in the company's position to build on momentum from encouraging clinical data and aims to execute corporate priorities for long-term success [5]

Core Insights - IN8bio, Inc. reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials for newly diagnosed glioblastoma (GBM), showing significant improvements in progression-free survival compared to historical standard-of-care data [1][4] Clinical Trial Results - Patients receiving DeltEx™ Drug-Resistant Immunotherapy γδ T cells (DeltEx DRI) demonstrated a median progression-free survival (mPFS) of 13.0 months, nearly double the 6.6 months observed in the standard-of-care (SOC) control cohort, representing a 97% improvement [4][5] - The median overall survival (mOS) for DeltEx DRI patients is currently at 17.2+ months, compared to 13.2 months for SOC, indicating a 30.3% increase [4][5] - Eight out of fourteen DeltEx DRI patients (57%) remained progression-free longer than their expected overall survival based on age and MGMT status, while only one patient (10%) in the control group achieved this [5] Safety Profile - The DeltEx DRI treatment exhibited a well-tolerated safety profile, with no severe adverse events (SAEs) or dose-limiting toxicities (DLTs) reported [4][6] - No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity (ICANS) was observed, further supporting the safety of the treatment [6][9] Immune Response Insights - Elevated levels of γδ T cells were observed in treated patients, along with immune cell infiltration within tumors and broader systemic immune activation, suggesting a significant immune impact [7] - The localized intracranial delivery of DeltEx DRI may drive systemic immune responses, which is crucial for combating GBM, a disease characterized by rapid progression and poor outcomes [7] Company Background - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, including programs targeting acute myeloid leukemia and glioblastoma [8]